Nuvectis Pharma, Inc. (NVCT) is a Healthcare stock trading at $23.49 (as of 2026-08-21), with a market capitalization of $765.34M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
| Price | $23.49 |
| Market Cap | $765.34M |
| Price / Book | 84.27 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | VANGUARD GROUP INC ($6.38M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Ron Bentsur |
| Employees | 13 |
| Country | US |
| IPO Date | 2022-02-04 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.